



## **STRATEGIC DEVELOPMENT PLAN** **策略發展計劃**

This Plan summarises our mission, business, programme development directions and our portfolio.

本文件概括香港賽馬會中藥研究院的使命、業務、項目發展方向和項目組合。

### **OUR MISSION 使命**

Our mission is to spearhead the development of Chinese medicine as a high value-added industry for Hong Kong through the promotion and coordination of related activities and strategic support for scientific and evidence-based development programmes.

本院的使命是透過推動和統籌與中藥發展相關的活動，支援以科學及實証為本的中藥研發項目，將中藥業發展成為香港的其中一個高增值行業。

### **OUR BUSINESS 本院的業務**

2. The scope of our business embraces the following:-

本院的業務範圍包括：

- (a) Funding R&D projects leveraging scientific and clinical expertise and available resources according to our Funding Plan and Programme Directions;

根據我們的撥款計劃和項目發展方向，撥款支持研發項目，有效協調科研專業人才和現有的資源；

- (b) Promoting commercialization of R&D outputs via licensing, spin-off, joint ventures with industry to effect technology transfer;

透過特許經營、創辦新公司、與業界開辦合資企業等形式進行研發項目成果的商業化；

- (c) Promoting Chinese medicine among the research and business communities, government offices and public institutions in Hong Kong, Mainland and abroad;

向本地，內地及海外的科研界、業界，政府部門和相關機構，推廣中醫藥；

- (d) Raising awareness and stimulating interests among our stakeholders via R & D projects, forum group discussions and other specific activities.

透過實施研發項目，舉辦論壇及其他相關活動，來提高和激發相關人士對中醫藥的認識和興趣。

### **Funding Plan** 撥款計劃

3. We have a pledged donation of HK\$500 million (“the Fund”) from The Hong Kong Jockey Club Charities Trust to support research projects and specific activities.

本院得到香港賽馬會慈善信託基金承諾捐款港幣 5 億元，支持研究項目和相關的活動。

4. Our prime focus for research in Chinese medicine is on aging and unmet medical needs of global medical concerns. The majority of the Fund will be used to support areas identified for strategic development (see Our Portfolio). Centralised facilities or shared platforms, spanning quality control, information, technology, regulatory and business support, will be set up to support projects. The remaining part of the Fund will be used to support other worthwhile projects and for IP management and technology transfer.

本院主要集中研究國際關注的老年疾病及難治性疾病，大部份的經費會用於支持指定的策略發展領域(見我們的項目組合)。我們將設立共享設施或平台，包括品質控制、資訊、應用技術、法規支援及商業推動等支持本院撥款之項目發展。其餘部份經費會用於支持具有發展潛力的項目，以及用於知識產權的管理和技術轉讓。

### **Business Model** 業務模式

5. Our prime business is to turn science into intellectual properties for technology transfer. We leverage our local resources and will seek to establish collaborations with the international research and industrial communities. Our funded projects are led by experienced scientists and professionals.

我們主要的業務目標為將科研轉化為知識產權以實現技術轉讓。我們將善用本地的資源，同時會尋求與國際知名研究機構建立合作伙伴關係。本院撥款支持的項目均有資深科學家和專業人仕領導。

6. Our strategies premise on (i) building areas of excellence and capabilities in research and quality control of Chinese medicine; (ii) generating intellectual properties, including patents and other forms of IP; and (iii) collaboration, effective technology transfer and exchange of research and business-relevant information.

我們的策略包括 i)在中藥研究和質控方面建立卓越研究領域，增強研究力量；ii)獲取一批包括專利等形式的知識產權；及 iii) 廣泛建立合作關係，有效實施技術轉讓及推動研究與商業相關的訊息交流。

7. The nature and development times of projects vary. We aim to broaden our IP portfolio and will collaborate with partners to maximise the value of our funded projects for research and commercialisation purposes. Profit sharing agreements will take into account the contributions of collaborators and will be negotiated on a case-by-case basis.

由於每個項目的性質和研發時間不同，我們將拓寬項目知識產權的組合，並與合作伙伴緊密合作，以達到最大限度的體現項目價值及成果商業化的目標。項目商業化後所得的利潤，將依據項目的性質和參考合作各方貢獻比例的大小，協商分配。

## **PROGRAMME DIRECTIONS 項目發展方向**

8. We fund R&D projects and specific activities according to the following related directions: -

本院將根據以下之發展方向，撥款支持研發項目：-

- (a) Development of products based on Chinese medicine to proof of principle fulfilling international regulatory requirements for safety, quality and efficacy

發展以中醫藥理論為基礎的產品，並須達到國際規範要求以確保其安全，品質和成效性

- (b) Scientific investigation, validation, quality profiling and characterisation of Chinese medicine

實施中藥的系統研究、確認、質量鑒別和標準化

- (c) Chinese medicine information exchange supporting scientific and industry development

中醫藥資訊交流以支持學術界及業界的發展

## **OUR PROJECT PORTFOLIO 項目組合**

9. We are building a portfolio in line to our funding plan and programme directions. During the start-up phase, we have initiated a few projects in collaboration with local universities and Mainland parties. As we enter a new phase of development, we are interested in research that fall within endocrinology and neuroscience, leveraging the research strengths and business resources within and outside Hong Kong. Other worthy areas of investigation will also be supported.

我們正在建立一整套符合本院撥款計劃和發展方向的項目組合。本院在起步階段，已與本地和內地相關研究機構合作，實施了數個研發項目。由於本院已踏入又一新的發展階段，我們將銳意開展與“內分泌”和“神經科學”有關的研發項目，以其滙集本地與海外的科研力量和業界的資源。其他的一些值得研究的領域亦會考慮支持。

10. Please visit our web [www.hkjcicm.org](http://www.hkjcicm.org) for research highlights of our funded projects.

有關項目簡報，請瀏覽本院網頁 [www.hkjcicm.org](http://www.hkjcicm.org)。

## **CONTACTS 聯絡詳情**

11. For enquiry and comments, please contact  
如有任何疑問，請聯絡本院的項目管理人員：

**Mr Andrew Cheng, MPhil 鄭先生**

Tel.: (852) 3406 2874 e-mail: [andrewch@hkjcicm.org](mailto:andrewch@hkjcicm.org)

電話：(852) 3406 2874 電郵：[andrewch@hkjcicm.org](mailto:andrewch@hkjcicm.org)

Hong Kong Jockey Club Institute of Chinese Medicine Limited (June 2003)  
香港賽馬會中藥研究院有限公司 (二零零三年 六月)